Connect Biopharma Holdings Limited (CNTB)
CNTBNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$0.6724
-0.0165 (-2.40%) today
Regular session, Nov 12, 10:12 AM ET
- Market cap
- $42.34m
- P/E
- –
- EPS, last 4 quarters
- $-1.19
- Dividend yield
- –
- Day range
- $0.6600 to $0.7200
- 52-week range
- $0.6800 to $3.82
- Average volume
- –
- Previous close
- $0.6889
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $6.86, +920.2% from here
Earnings
next estimate $-0.2700Next report
Sep 2025
-29.2%
Dec 2025
+10.0%
Mar 2026
-17.2%
Jun 2026
+15.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $16.0k | – | $169.0k | $2.77m |
| Gross profit | $16.0k | – | $169.0k | $2.77m |
| Operating income | -$17.68m | -$15.53m | -$19.61m | -$17.60m |
| Net income | -$17.20m | -$15.11m | -$19.40m | -$17.28m |
News
8 latest- Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround Zacks · Oct 22, 2026
- Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom FisherZacks · Oct 19, 2026
- Connect Biopharma COPD Study Shows 81% Cut in Treatment FailuresMarketBeat · Oct 4, 2026
- Biotech Stocks Surge - NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON RTTNews · Sep 30, 2026
- Connect Biopharma Reports Positive Phase 2 Rademikibart Data In Acute COPD RTTNews · Sep 30, 2026
- Connect Biopharma Advances Rademikibart Toward Phase 3 In COPD RTTNews · Sep 30, 2026
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead RTTNews · Sep 18, 2026
- Connect Biopharma Reports Positive Phase 2 Data For Rademikibart In Acute Asthma Exacerbations RTTNews · Sep 15, 2026
The company
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4R. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- connectbiopharm.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.